FDA Investigator Jean M Mulinde, MD
Jean M Mulinde, MD has conducted inspections on 8 sites in 3 countries as of 31 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
31 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
Cayman Islands,
United Kingdom of Great Britain and Northern Ireland
FDA Investigators that have inspected at least one site in common with Jean M Mulinde, MD:
Addam S Reynolds,
Ana P Barido,
Annet R Rajan,
Anthony J Donato,
Barbara D Wright,
Bei Yu,
Brandon L Mariner,
Byungja E Marciante,
Charles R Bonapace, PhD,
Christina P Burkhart,
Craig A Garmendia,
Cynthia F Kleppinger, MD,
Daniel J Grabicki,
Daniel J Roberts,
David L Chon,
Dawn L Wydner,
Douglas C Kovacs,
Ekaterina Allen,
Emest F Bizjak,
Frederick F Razzaghi,
Guerlain Ulysse,
Hector Jcolon Torres,
James R Birkenstamm,
Jazmine N Brown,
Jenn W Sellers,
John Dan,
Jonee J Mearns,
Joy Rkozlowski Klena,
Justine Tomasso,
Kelli F Dobilas,
Kristy A Zielny,
Lauren Iacono Connors, PhD,
Lee Hong Pai Scherf,
Liming Zhang,
Lori S Lawless,
Marea K Harmon,
Michael R Klapal,
Michael Serrano,
Mra Mcculloughj,
Nancy L Rolli,
Nebil A Oumer,
Nina Yang,
Paul L Bellamy,
Peter R Lenahan,
Robin R Waller,
Shirley S Wen,
Walden H Lee,
Yangmin Ning
Jean M Mulinde, MD's Documents
Publish Date | Document Type | Title |
---|---|---|
June, 2017 | EIR | Rho, Inc. - EIR, 2017-06-30 |
December, 2015 | EIR | Eisai, Inc. - EIR, 2015-12-09 |
December, 2015 | FDA 483 Response | Eisai, Inc. - Form 483R, 2015-12-18 |
June, 2017 | FDA 483 | Rho, Inc. - Form 483, 2017-06-30 |
June, 2008 | FDA 483 | Johnson & Johnson Pharmaceutical Research & Development, LLC - Form 483, 2008-06-12 |
February, 2018 | FDA 483 | Eisai, Inc. - Form 483, 2018-02-16 |
June, 2008 | EIR | Johnson & Johnson Pharmaceutical Research & Development, LLC - EIR, 2008-06-12 |
December, 2015 | FDA 483 | Eisai, Inc. - Form 483, 2015-12-09 |
August, 2016 | FDA 483 | Merck Sharp & Dohme LLC - Form 483, 2016-08-26 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more